Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

被引：0

作者：

Lakhwani, Sunil ^{[1
]}

Mateos, Maria Victoria ^{[2
]}

Martinez-Lopez, Joaquin ^{[3
]}

Paiva, Bruno ^{[4
]}

Rosinol Dachs, Laura ^{[5
]}

Martinez, Rafael ^{[6
]}

Oriol, Albert ^{[7
]}

Bargay, Joan ^{[8
]}

Gonzalez-Montes, Yolanda ^{[9
]}

Gironella, Mercedes ^{[10
]}

Encinas, Cristina ^{[11
]}

Martin, Jesus ^{[12
]}

Jarque, Isidro ^{[13
]}

Granell, Miquel ^{[14
]}

Abella, Eugenia ^{[15
]}

Garcia-Mateo, Aranzazu ^{[16
]}

Hernandez-Rivas, Jose angel ^{[17
]}

Ramila, Elena ^{[18
]}

Krsnik, Isabel ^{[19
]}

Casado Montero, Luis Felipe ^{[20
]}

De Arriba, Felipe ^{[21
]}

Palomera, Luis ^{[22
]}

Sampol, Antonia ^{[23
]}

Moraleda, Jose Maria ^{[24
]}

Casanova, Maria ^{[25
]}

Delgado, Pilar ^{[26
]}

Lafuente, Ana ^{[27
]}

Amutio, Elena ^{[28
]}

Lopez-Martinez, Aurelio ^{[29
]}

Altes, Albert ^{[30
]}

Ruiz, M. angeles ^{[31
]}

Alegre, Adrian ^{[32
]}

Lopez-Anglada, Lucia ^{[33
]}

de la Cruz, Javier ^{[34
]}

Alonso Fernandez, Rafael ^{[3
]}

Blade Creixenti, Joan ^{[5
]}

Lahuerta, Juan-Jose ^{[34
]}

San-Miguel, Jesus ^{[4
]}

Hernandez, Miguel-Teodoro ^{[1
]}

机构：

[1] Univ La Laguna, Hosp Univ Canarias, Tenerife, Spain

[2] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[3] Univ Complutense Madrid, Spanish Natl Canc Res Ctr CNIO, Hosp Univ 12 Octubre, Madrid, Spain

[4] Canc Ctr Clin Univ Navarra CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[5] Hosp Clin Barcelona, Amyloidosis & Myeloma Unit, Barcelona, Spain

[6] Hosp Univ San Carlos, Madrid, Spain

[7] Hosp Badalona Germans Trias i Pujol, Inst Catala Oncol, Inst Josep Carreras, Badalona, Spain

[8] Hosp Son Llatzer, IdIsBa, Palma De Mallorca, Spain

[9] Hosp Univ Dr Josep Trueta, ICO Girona, Hosp Universitari Dr, Girona, Spain

[10] Hosp Univ Vall dHebron, Barcelona, Spain

[11] Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain

[12] Hosp Univ Virgen Rocio, Seville, Spain

[13] Hosp Univ & Politecn La Fe, Valencia, Spain

[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[15] Hosp Mar Barcelona, Barcelona, Spain

[16] Hosp Gen Segovia, Segovia, Spain

[17] Hosp Univ Infanta Leonor, Madrid, Spain

[18] Hosp Parc Tauli, Sabadell, Barcelona, Spain

[19] Hosp Univ Puerta de Hierro, Madrid, Spain

[20] Hosp Gen Univ Toledo, Toledo, Spain

[21] Univ Murcia, Hosp Morales Meseguer, IMIB Pascual Parrilla, Murcia, Spain

[22] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

[23] Hosp Univ Son Espases, Palma De Mallorca, Spain

[24] Univ Murcia, Hosp Clin Univ Virgen Arrixaca, Dept Radiol, Murcia, Spain

[25] Hosp Costa Sol, Marbella, Spain

[26] Hosp Miguel Servet, Zaragoza, Spain

[27] Hosp Virgen Salud, Toledo, Spain

[28] Hosp Univ Cruces, Bilbao, Spain

[29] Hosp Arnau Vilanova, Lleida, Spain

[30] Xarxa Assistencial Manresa, Hosp Althaia, Manresa, Spain

[31] Hosp Francesc de Borja, Valencia, Spain

[32] Hosp Univ La Princesa, Madrid, Spain

[33] Unidad Terapias Avanzadas Consejeria Sanidad Comun, Madrid, Spain

[34] Hosp Univ 12 Octubre, Inst Invest Sanitaria, Madrid, Spain

来源：

ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 12期

关键词：

Immunoparesis; Myeloma; Minimal residual disease; Immunoglobulin; STEM-CELL TRANSPLANTATION; MONOCLONAL GAMMOPATHY; RESPONSE CRITERIA; IMMUNOGLOBULINS; PROGRESSION; CANCER;

D O I：

10.1007/s00277-024-06031-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact of IP recovery and its association with minimal residual disease (MRD) in a series of 113 newly diagnosed transplant-ineligible (NDTI) patients, that received fix duration treatment (18 cycles of VMP/lenalidomide-dexamethasone) within the PETHEMA/GEM2010MAS65 trial and who achieved CR or VGPR. Immunoglobulin levels were measured at diagnosis, at the end of treatment (after cycle 18th) and during subsequent follow up whereas MRD was analyzed only at the end of the treatment (after cycle 18th). We found that patients who had IP at diagnosis and recovered it during or after treatment had longer progression free survival (PFS) [p < 0.001; HR 0.32 (0.19-0.52)] and longer overall survival (OS) [p = 0.007; HR 0.40 (0.20-0.80)] compared to those who failed to recover it. When we analyzed IP recovery in MRD negative patients, we found that those cases with IP recovery had longer PFS [p = 0.007; HR 0.31 (0.13-0.76)] and longer OS [p = 0.012; HR 0.21 (0.06-0.80)] as compared to MRD negative patients but without IP recovery. In conclusion, IP recovery confers better prognosis in NDTI-MM patients with fixed duration treatment who achieve CR or VGPR and the prognostic value of MRD can be complemented when combined with IP recovery.

引用

页码：5651 / 5661

页数：11

共 30 条

[1] Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Avet-Loiseau, Herve
Ludwig, Heinz
Landgren, Ola
Paiva, Bruno
Morris, Chris
Yang, Hui
Zhou, Kefei
Ro, Sunhee
Mateos, Maria-Victoria
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) : E30 - E37
[2] Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, Giada
Munshi, Nikhil C.
[J]. BLOOD, 2015, 125 (20) : 3049 - 3058
[3] Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis
Chen, Ying
Chen, Zhe
Cao, Junjie
Lin, Li
Li, Jipeng
[J]. HEMATOLOGY, 2024, 29 (01)
[4] Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival
Davila, Julio
Gonzalez-Calle, Veronica
Escalante, Fernando
Cerda, Seila
Puig, Noemi
Garcia-Sanz, Ramon
Barez, Abelardo
Montes, Carmen
Lopez, Rosa
Maria Alonso, Jose
Aguilar, Carlos
Garcia-Mateo, Aranzazu
Labrador, Jorge
Aguilera, Carmen
Garcia-Coca, Alfonso
Hernandez, Roberto
Mateos, Maria-Victoria
Ocio, Enrique M.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 278 - 287
[5] Diaz-Rodriguez R, 2013, 55 NAT C SEHH CO 021
[6] International uniform response criteria for multiple myeloma
Durie, B. G. M.
Harousseau, J-L
Miguel, J. S.
Blade, J.
Barlogie, B.
Anderson, K.
Gertz, M.
Dimopoulos, M.
Westin, J.
Sonneveld, P.
Ludwig, H.
Gahrton, G.
Beksac, M.
Crowley, J.
Belch, A.
Boccadaro, M.
Turesson, I.
Joshua, D.
Vesole, D.
Kyle, R.
Alexanian, R.
Tricot, G.
Attal, M.
Merlini, G.
Powles, R.
Richardson, P.
Shimizu, K.
Tosi, P.
Morgan, G.
Rajkumar, S. V.
[J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
[7] Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
Eisfeld, Christine
Esseling, Eva
Wullenkord, Ramona
Khandanpour, Cyrus
Reusch, Julia
Mikesch, Jan-Henrik
Reicherts, Christian
Kerkhoff, Andrea
Schliemann, Christoph
Kessler, Torsten
Mesters, Rolf M.
Berdel, Wolfgang E.
Lenz, Georg
Stelljes, Matthias
[J]. ANNALS OF HEMATOLOGY, 2020, 99 (08) : 1907 - 1915
[8] Multicentre physiological reference intervals for serum concentrations of immunoglobulins A, G and M, complement C3c and C4 measured with Tina-Quant® reagents systems
Fuentes-Arderiu, Xavier
Alonso-Gregorio, Eduardo
Alvarez-Funes, Virtudes
Ambros-Marigomez, Carmen
Coca-Fabregas, Lluis
Cruz-Placer, Marta
Diaz-Fernandez, Julian
Pilar Pinel-Julian, Maria
Gutierrez-Cecchini, Beatriz
Herrero-Bernal, Pilar
Sempere-Alcocer, Marcos
Garcia-Caballero, Francisca
del Mar Larrea-Ortiz-Quintana, Maria
La-Torre-Marcellan, Pedro
del Senor Lopez-Velez, Maria
Mar-Medina, Carmen
Martin-Oncina, Javier
Victoria Rodriguez-Hernandez, Maria
Victoria Romero-Sotomayor, Maria
Serrano-Lopez, Candido
Sicilia-Enriquez-de-Salamanca, Adolfo
Maria Velasco-Romero, Ana
Juve-Cuxart, Santiago
[J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (03) : 387 - 390
[9] Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Gao, Wen
Li, Jie
Wu, Yin
Li, Yanchen
Leng, Yun
Liu, Aijun
Yang, Guangzhong
Tian, Ying
Wang, Huijuan
Wang, Guorong
Wu, Zhipeng
Ren, Zhangyong
Chen, Wenming
[J]. ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1177 - 1184
[10] Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients
Geng, Chuanying
Yang, Guangzhong
Wang, Huijuan
Wu, Yin
Leng, Yun
Zhou, Huixing
Zhang, Zhiyao
Jian, Yuan
Chen, Wenming
[J]. LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 883 - 890

← 1 2 3 →